Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:RNXT

RenovoRx Q2 2026 Earnings Report

RenovoRx logo
$0.96 +0.02 (+1.82%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.93 -0.03 (-2.74%)
As of 07/31/2026 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

RenovoRx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.08
Beat/Miss
N/A
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.70 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

RenovoRx Earnings Headlines

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
July 29 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335203/0/en/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-conference-call-on-august-12th-at-4-30-p-m-et.html
RenovoRx Stock Short Interest Report | NASDAQ:RNXT | Benzinga
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RNXT/short-interest
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
August 1 at 1:00 AM  |  Chaikin Analytics (Ad)
RenovoRx Stockholders Approve Directors and Equity Plan
June 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/renovorx-stockholders-approve-directors-and-equity-plan?utm_source=marketbeat.com&utm_medium=referral
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
June 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917084-renovorx-inc-rnxt-presents-at-iaccess-alpha-virtual-best-ideas-summer-investment-conference
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310469/0/en/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitabine-delivery-via-tamp-in-locally-advanced-pancreatic-cancer.html
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT) is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets.

Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.

View RenovoRx Profile
Earnings Tools